Mitochondrial Dysfunction in the Transition from NASH to HCC

被引:65
|
作者
Leveille, Melissa [1 ,2 ]
Estall, Jennifer L. [1 ,2 ,3 ]
机构
[1] IRCM, Quebec City, PQ H2W 1R7, Canada
[2] Univ Montreal, Fac Med, Quebec City, PQ H3G 2M1, Canada
[3] McGill Univ, Div Expt Med, Quebec City, PQ H4A 3J1, Canada
关键词
mitochondria; metabolism; liver; NAFLD; NASH; HCC; NONALCOHOLIC FATTY LIVER; PROLIFERATOR-ACTIVATED RECEPTOR; GAMMA-COACTIVATOR; 1-ALPHA; UNFOLDED PROTEIN RESPONSE; PLACEBO-CONTROLLED TRIAL; ONE-CARBON METABOLISM; HEPATOCELLULAR-CARCINOMA; OXIDATIVE STRESS; VITAMIN-E; ENDOPLASMIC-RETICULUM;
D O I
10.3390/metabo9100233
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The liver constantly adapts to meet energy requirements of the whole body. Despite its remarkable adaptative capacity, prolonged exposure of liver cells to harmful environmental cues (such as diets rich in fat, sugar, and cholesterol) results in the development of chronic liver diseases (including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)) that can progress to hepatocellular carcinoma (HCC). The pathogenesis of these diseases is extremely complex, multifactorial, and poorly understood. Emerging evidence suggests that mitochondrial dysfunction or maladaptation contributes to detrimental effects on hepatocyte bioenergetics, reactive oxygen species (ROS) homeostasis, endoplasmic reticulum (ER) stress, inflammation, and cell death leading to NASH and HCC. The present review highlights the potential contribution of altered mitochondria function to NASH-related HCC and discusses how agents targeting this organelle could provide interesting treatment strategies for these diseases.
引用
收藏
页数:28
相关论文
共 50 条
  • [21] HCC and NASH: How strong is the clinical demonstration?
    Rosmorduc, O.
    Fartoux, L.
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2012, 36 (03) : 202 - 208
  • [22] Hepatic CDP-diacylglycerol synthase 2 deficiency causes mitochondrial dysfunction and promotes rapid progression of NASH and fibrosis
    Xu, Jiesi
    Chen, Siyu
    Wang, Wei
    Lam, Sin Man
    Xu, Yang
    Zhang, Shaohua
    Pan, Huimin
    Liang, Jingjing
    Huang, Xiahe
    Wang, Yu
    Li, Ting
    Jiang, Yuqiang
    Wang, Yingchun
    Ding, Mei
    Shui, Guanghou
    Yang, Hongyuan
    Huang, Xun
    SCIENCE BULLETIN, 2022, 67 (03) : 299 - 314
  • [23] P53 and VEGF are promising biomarkers for sorafenib efficacy in an experimental model of NASH-related HCC
    Nassar-Reis, Joao Pedro
    Umeta, Pedro Fukui
    Stefano, Jose Tadeu
    Longatto-Filho, Adhemar
    Carrilho, Flair Jose
    Alves, Venancio Avancini Ferreira
    Cogliati, Bruno
    Oliveira, Claudia P.
    JOURNAL OF MOLECULAR HISTOLOGY, 2023, 54 (05) : 473 - 488
  • [24] Metformin Actions on the Liver: Protection Mechanisms Emerging in Hepatocytes and Immune Cells against NASH-Related HCC
    Zhang, Yueqi
    Wang, Hongbing
    Xiao, Hua
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (09)
  • [25] Mitochondrial dysfunction in NASH: Causes, consequences and possible means to prevent it
    Begriche, K
    Igoudjil, A
    Pessayre, D
    Fromenty, B
    MITOCHONDRION, 2006, 6 (01) : 1 - 28
  • [26] From MASH to HCC: the role of Gas6/TAM receptors
    Apostolo, Daria
    Ferreira, Luciana L.
    Vincenzi, Federica
    Vercellino, Nicole
    Minisini, Rosalba
    Latini, Federico
    Ferrari, Barbara
    Burlone, Michela E.
    Pirisi, Mario
    Bellan, Mattia
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [27] The genetic background shapes the susceptibility to mitochondrial dysfunction and NASH progression
    Benegiamo, Giorgia
    von Alvensleben, Giacomo V. G.
    Rodriguez-Lopez, Sandra
    Goeminne, Ludger J. E.
    Bachmann, Alexis M.
    Morel, Jean-David
    Broeckx, Ellen
    Ma, Jing Ying
    Carreira, Vinicius
    Youssef, Sameh A.
    Azhar, Nabil
    Reilly, Dermot F.
    D'Aquino, Katharine
    Mullican, Shannon
    Bou-Sleiman, Maroun
    Auwerx, Johan
    JOURNAL OF EXPERIMENTAL MEDICINE, 2023, 220 (04)
  • [28] Natural history of NASH and HCC
    Negro, Francesco
    LIVER INTERNATIONAL, 2020, 40 : 72 - 76
  • [29] Resection of NAFLD/NASH-related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC Due to Other Etiologies
    Chaudhary, Surendra Pal
    Reyes, Stephanie
    Chase, Matthew L.
    Govindan, Aparna
    Zhao, Lei
    Luther, Jay
    Bhan, Irun
    Bethea, Emily
    Franses, Joseph W.
    Paige Walsh, Elizabeth
    Anne Dageford, Leigh
    Kimura, Shoko
    Elias, Nahel
    Yeh, Heidi
    Markman, James
    Bozorgzadeh, Adel
    Tanabe, Kenneth
    Ferrone, Cristina
    Zhu, Andrew X.
    Andersson, Karin
    Thiim, Michael
    Antonio Catalano, Onofrio
    Kambadakone, Avinash
    Vagefi, Parsia A.
    Qadan, Motaz
    Pratt, Daniel
    Hashemi, Nikroo
    Corey, Kathleen E.
    Misdraji, Joseph
    Goyal, Lipika
    Clark, Jeffrey W.
    ONCOLOGIST, 2023, : 341 - 350
  • [30] Mitochondrial Dysfunction in Atherosclerosis
    Peng, Wenxi
    Cai, Guoding
    Xia, Yiping
    Chen, Jinna
    Wu, Peng
    Wang, Zuo
    Li, Guohua
    Wei, Dangheng
    DNA AND CELL BIOLOGY, 2019, 38 (07) : 597 - 606